UA83467C2 - Соединения пиперидинила, которые селективно связывают рецепторы интегрина - Google Patents

Соединения пиперидинила, которые селективно связывают рецепторы интегрина Download PDF

Info

Publication number: UA83467C2
Authority: UA; Ukraine
Prior art keywords: vaveze; aai; azabzsi; yair; oei
Prior art date: 2002-08-16

Application number

UAA200502396A

Other languages

English (en)

Ukrainian (uk)

Inventor

Корте Барт Де

Уильям А. Кинни

Шайямали Хош

Original Assignee

Янссен Фармацевтика Н.В.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-16

Filing date

2003-08-15

Publication date

2008-07-25

2003-08-15 Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.

2008-07-25 Publication of UA83467C2 publication Critical patent/UA83467C2/ru

Links

125000003386 piperidinyl group Chemical group 0.000 title abstract description 3
102000006495 integrins Human genes 0.000 title abstract 3
108010044426 integrins Proteins 0.000 title abstract 3
230000004438 eyesight Effects 0.000 claims description 2
230000008449 language Effects 0.000 claims description 2
244000205754 Colocasia esculenta Species 0.000 claims 3
235000006481 Colocasia esculenta Nutrition 0.000 claims 3
101100463789 Mus musculus Pagr1a gene Proteins 0.000 claims 3
241001116498 Taxus baccata Species 0.000 claims 3
241000895811 Myza Species 0.000 claims 2
210000002268 wool Anatomy 0.000 claims 2
NUMXHEUHHRTBQT-AATRIKPKSA-N 2,4-dimethoxy-1-[(e)-2-nitroethenyl]benzene Chemical compound COC1=CC=C(\C=C\[N+]([O-])=O)C(OC)=C1 NUMXHEUHHRTBQT-AATRIKPKSA-N 0.000 claims 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims 1
UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 1
230000001404 mediated effect Effects 0.000 abstract 1
-1 tetrahydropyrimidin-2-yl Chemical group 0.000 description 25
150000001875 compounds Chemical class 0.000 description 21
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 12
241001446467 Mama Species 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
241000343235 Maso Species 0.000 description 9
102100027730 Endogenous retrovirus group K member 19 Rec protein Human genes 0.000 description 8
101001064123 Homo sapiens Endogenous retrovirus group K member 19 Env polyprotein Proteins 0.000 description 8
101000893974 Homo sapiens Endogenous retrovirus group K member 19 Gag polyprotein Proteins 0.000 description 8
101000956190 Homo sapiens Endogenous retrovirus group K member 19 Pro protein Proteins 0.000 description 8
101000580915 Homo sapiens Endogenous retrovirus group K member 19 Rec protein Proteins 0.000 description 8
101001066689 Homo sapiens Integrase Proteins 0.000 description 8
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 8
229950001870 spizofurone Drugs 0.000 description 8
229920001817 Agar Polymers 0.000 description 7
239000008272 agar Substances 0.000 description 7
125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
AGJBKFAPBKOEGA-UHFFFAOYSA-M 2-methoxyethylmercury(1+);acetate Chemical compound COCC[Hg]OC(C)=O AGJBKFAPBKOEGA-UHFFFAOYSA-M 0.000 description 3
241000223477 Abea Species 0.000 description 3
241000258740 Abia Species 0.000 description 3
241000726103 Atta Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
244000236580 Psidium pyriferum Species 0.000 description 3
235000013929 Psidium pyriferum Nutrition 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
238000000746 purification Methods 0.000 description 3
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 2
LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
241000408551 Meza Species 0.000 description 2
101100245161 Mus musculus Prpf19 gene Proteins 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
244000269722 Thea sinensis Species 0.000 description 2
101000577937 Xenopus laevis Midkine-A Proteins 0.000 description 2
229940125758 compound 15 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
RLLPVAHGXHCWKJ-IEBWSBKVSA-N (3-phenoxyphenyl)methyl (1s,3s)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(Cl)Cl)[C@@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-IEBWSBKVSA-N 0.000 description 1
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
241001287917 Aaages Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000611750 Coregonus kiyi Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
235000017788 Cydonia oblonga Nutrition 0.000 description 1
244000089409 Erythrina poeppigiana Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101150004665 GCH1 gene Proteins 0.000 description 1
239000001358 L(+)-tartaric acid Substances 0.000 description 1
244000208060 Lawsonia inermis Species 0.000 description 1
101100228519 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gch-1 gene Proteins 0.000 description 1
241001344466 Peisos Species 0.000 description 1
241001442654 Percnon planissimum Species 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
241000944367 Pyza Species 0.000 description 1
241000269435 Rana <genus> Species 0.000 description 1
235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
101100056293 Rattus norvegicus Akr7a2 gene Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
YLBMNMLHAAOXAL-UHFFFAOYSA-N aziv Chemical compound O1C(C)=C(O)C(=O)CC1OC1C2(C)CCC3(C)C4(C)CCC5C(C)(CO)C(OC6C(C(O)C(O)C(O6)C(O)=O)OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC=C3C2CC(C)(C)C1 YLBMNMLHAAOXAL-UHFFFAOYSA-N 0.000 description 1
229940106943 azor Drugs 0.000 description 1
229940058679 baza Drugs 0.000 description 1
YKGYQYOQRGPFTO-UHFFFAOYSA-N bis(8-methylnonyl) hexanedioate Chemical compound CC(C)CCCCCCCOC(=O)CCCCC(=O)OCCCCCCCC(C)C YKGYQYOQRGPFTO-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
241001233037 catfish Species 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
YOMFVLRTMZWACQ-UHFFFAOYSA-N ethyltrimethylammonium Chemical compound CC[N+](C)(C)C YOMFVLRTMZWACQ-UHFFFAOYSA-N 0.000 description 1
210000000720 eyelash Anatomy 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
241000238565 lobster Species 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
229960005311 telbivudine Drugs 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
NFRBUOMQJKUACC-UHFFFAOYSA-N triethyl(pentyl)azanium Chemical compound CCCCC[N+](CC)(CC)CC NFRBUOMQJKUACC-UHFFFAOYSA-N 0.000 description 1
239000008434 yi-zhi Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Surgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)

UAA200502396A 2002-08-16 2003-08-15 Соединения пиперидинила, которые селективно связывают рецепторы интегрина UA83467C2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40423902P	2002-08-16	2002-08-16
PCT/US2003/025782 WO2004020435A1 (en)	2002-08-16	2003-08-15	Piperidinyl compounds that selectively bind integrins

Publications (1)

Publication Number	Publication Date
UA83467C2 true UA83467C2 (ru)	2008-07-25

Family

ID=31978252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200502396A UA83467C2 (ru)	2002-08-16	2003-08-15	Соединения пиперидинила, которые селективно связывают рецепторы интегрина

Country Status (24)

Country	Link
US (1)	US20040077684A1 (ru)
EP (1)	EP1539739B1 (ru)
JP (1)	JP4554364B2 (ru)
KR (1)	KR20050031464A (ru)
CN (1)	CN100506815C (ru)
AR (1)	AR041010A1 (ru)
AT (1)	ATE489378T1 (ru)
AU (2)	AU2003259891A1 (ru)
BR (1)	BR0313534A (ru)
CA (1)	CA2496127C (ru)
CR (1)	CR7692A (ru)
CY (1)	CY1111194T1 (ru)
DE (1)	DE60335118D1 (ru)
DK (1)	DK1539739T3 (ru)
ES (1)	ES2355139T3 (ru)
IL (1)	IL166534A (ru)
MX (1)	MXPA05001859A (ru)
NO (1)	NO332036B1 (ru)
PL (1)	PL219749B1 (ru)
PT (1)	PT1539739E (ru)
RU (1)	RU2333210C2 (ru)
SI (1)	SI1539739T1 (ru)
UA (1)	UA83467C2 (ru)
WO (1)	WO2004020435A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040224986A1 (en)	2002-08-16	2004-11-11	Bart De Corte	Piperidinyl targeting compounds that selectively bind integrins
US7351711B2 (en) *	2003-07-31	2008-04-01	Janssen Pharmaceutical, N.V.	Tricyclic indanyls as integrin inhibitors
EP1734996B1 (en) *	2004-04-02	2013-05-22	The Regents of The University of California	Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
BRPI0519739A2 (pt) *	2004-12-30	2009-03-10	Cinv Ag	combinaÇço compreendendo um agente fornecendo um sinal, um material de implante e uma droga
JP5057994B2 (ja) *	2005-01-06	2012-10-24	ジーイー・ヘルスケア・アクスイェ・セルスカプ	光学イメージング
US8372399B2 (en) *	2006-08-31	2013-02-12	Cardiac Pacemakers, Inc.	Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) *	2006-08-31	2008-03-06	Cardiac Pacemakers, Inc.	Methods and devices employing vap-1 inhibitors
US8636995B2 (en) *	2006-08-31	2014-01-28	Cardiac Pacemakers, Inc.	Methods and devices to regulate stem cell homing
PT2178858E (pt) *	2007-08-02	2012-02-24	Recordati Ireland Ltd	Novos compostos heterocíclicos como antagonistas de mglu5
CA2703876A1 (en) *	2007-10-30	2009-05-07	Janssen Pharmaceutica, N.V.	Enantioselective process for preparing a substituted alkanoic acid
JP5637855B2 (ja) *	2007-11-08	2014-12-10	ザジェネラルホスピタルコーポレイション	蛋白尿症の治療のための方法及び組成物
CN102481347A (zh)	2009-07-24	2012-05-30	加州大学董事会	治疗和预防整合素αvβ5相关疾病的方法及组合物
RS64535B1 (sr)	2013-09-24	2023-09-29	Fujifilm Corp	Farmaceutska kompozicija jedinjenja koje sadrži azot ili njegovu so, ili njihov kompleks sa metalom
JP2019530678A (ja)	2016-09-18	2019-10-24	エイチリーモフィットキャンサーセンターアンドリサーチインスティテュートインコーポレイテッド	Ｙａｐ１のｏｃｔ４との相互作用を標的とするｙａｐ１阻害剤
BR112019009293A2 (pt) *	2016-11-08	2019-07-30	Bristol-Myers Squibb Company	pirrol amidas como inibidores de integrina alfa v
EP3538527B1 (en) *	2016-11-08	2021-10-13	Bristol-Myers Squibb Company	Azole amides and amines as alpha v integrin inhibitors
KR102891803B1 (ko)	2017-02-28	2025-11-28	모픽 테라퓨틱, 인코포레이티드	αvβ6 인테그린 억제제
EP3760202A1 (en) *	2017-02-28	2021-01-06	Morphic Therapeutic, Inc.	Inhibitors of (alpha-v)(beta-6) integrin
PE20211450A1 (es)	2018-03-14	2021-08-05	H Lee Moffitt Cancer Ct & Res	Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4
JP7540998B2 (ja)	2018-08-29	2024-08-27	モーフィックセラピューティック，インコーポレイテッド	αｖβ６インテグリンの阻害
UY38352A (es)	2018-08-29	2020-03-31	Morphic Therapeutic Inc	Inhibidores de integrina alfavbeta6
CN120282949A (zh) *	2023-09-28	2025-07-08	云合智药（苏州）生物科技有限公司	靶向整合素的化合物及其在RNAi剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN148482B (ru) *	1977-06-03	1981-03-07	Pfizer
US6004554A (en) *	1992-03-05	1999-12-21	Board Of Regents, The University Of Texas System	Methods for targeting the vasculature of solid tumors
US5474765A (en) *	1992-03-23	1995-12-12	Ut Sw Medical Ctr At Dallas	Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5902795A (en) *	1992-06-16	1999-05-11	Trustees Of Tufts College	Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5340798A (en) *	1992-10-14	1994-08-23	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5753659A (en) *	1993-03-29	1998-05-19	Zeneca Limited	Heterocyclic compouds
US5700801A (en) *	1994-12-23	1997-12-23	Karl Thomae, Gmbh	Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE19516483A1 (de) *	1995-05-05	1996-11-07	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
DE19613933A1 (de) *	1996-04-06	1997-10-09	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
US5919792A (en) *	1996-10-30	1999-07-06	Merck & Co., Inc.	Integrin antagonists
DE69830806T2 (de) *	1997-12-17	2006-04-27	Merck & Co., Inc.	Integrinrezeptor antagonisten
US6211191B1 (en) *	1997-12-17	2001-04-03	Merck & Co., Inc.	Integrin receptor antagonists
EP1091945A1 (en) *	1998-06-29	2001-04-18	Du Pont Pharmaceuticals Company	Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6887468B1 (en) *	1999-04-28	2005-05-03	Board Of Regents, The University Of Texas System	Antibody kits for selectively inhibiting VEGF
US6776796B2 (en) *	2000-05-12	2004-08-17	Cordis Corportation	Antiinflammatory drug and delivery device

2003
- 2003-08-15 US US10/641,964 patent/US20040077684A1/en not_active Abandoned
- 2003-08-15 CA CA2496127A patent/CA2496127C/en not_active Expired - Fee Related
- 2003-08-15 MX MXPA05001859A patent/MXPA05001859A/es active IP Right Grant
- 2003-08-15 AR ARP030102976A patent/AR041010A1/es unknown
- 2003-08-15 KR KR1020057001657A patent/KR20050031464A/ko not_active Ceased
- 2003-08-15 CN CNB038240904A patent/CN100506815C/zh not_active Expired - Fee Related
- 2003-08-15 SI SI200331951T patent/SI1539739T1/sl unknown
- 2003-08-15 PT PT03791686T patent/PT1539739E/pt unknown
- 2003-08-15 EP EP03791686A patent/EP1539739B1/en not_active Expired - Lifetime
- 2003-08-15 UA UAA200502396A patent/UA83467C2/ru unknown
- 2003-08-15 DE DE60335118T patent/DE60335118D1/de not_active Expired - Lifetime
- 2003-08-15 AT AT03791686T patent/ATE489378T1/de active
- 2003-08-15 BR BR0313534-9A patent/BR0313534A/pt not_active IP Right Cessation
- 2003-08-15 DK DK03791686.3T patent/DK1539739T3/da active
- 2003-08-15 JP JP2004532905A patent/JP4554364B2/ja not_active Expired - Fee Related
- 2003-08-15 AU AU2003259891A patent/AU2003259891A1/en not_active Abandoned
- 2003-08-15 RU RU2005104115/04A patent/RU2333210C2/ru not_active IP Right Cessation
- 2003-08-15 WO PCT/US2003/025782 patent/WO2004020435A1/en not_active Ceased
- 2003-08-15 ES ES03791686T patent/ES2355139T3/es not_active Expired - Lifetime
- 2003-08-15 PL PL375562A patent/PL219749B1/pl unknown
2005
- 2005-01-27 IL IL166534A patent/IL166534A/en not_active IP Right Cessation
- 2005-02-15 CR CR7692A patent/CR7692A/es unknown
- 2005-03-11 NO NO20051273A patent/NO332036B1/no not_active IP Right Cessation
2010
- 2010-10-25 AU AU2010236002A patent/AU2010236002B2/en not_active Ceased
2011
- 2011-02-09 CY CY20111100158T patent/CY1111194T1/el unknown

Also Published As

Publication number	Publication date
DE60335118D1 (de)	2011-01-05
MXPA05001859A (es)	2005-06-03
EP1539739B1 (en)	2010-11-24
IL166534A0 (en)	2006-01-15
RU2333210C2 (ru)	2008-09-10
AR041010A1 (es)	2005-04-27
ES2355139T3 (es)	2011-03-23
AU2010236002A1 (en)	2010-11-11
CY1111194T1 (el)	2015-06-11
CR7692A (es)	2009-01-14
NO332036B1 (no)	2012-06-04
CN100506815C (zh)	2009-07-01
KR20050031464A (ko)	2005-04-06
PL375562A1 (en)	2005-11-28
CN1688572A (zh)	2005-10-26
AU2003259891A1 (en)	2004-03-19
JP2005539049A (ja)	2005-12-22
EP1539739A1 (en)	2005-06-15
JP4554364B2 (ja)	2010-09-29
CA2496127A1 (en)	2005-02-16
AU2010236002B2 (en)	2012-05-03
WO2004020435A1 (en)	2004-03-11
PL219749B1 (pl)	2015-07-31
NO20051273L (no)	2005-05-10
PT1539739E (pt)	2011-01-05
RU2005104115A (ru)	2005-08-27
ATE489378T1 (de)	2010-12-15
US20040077684A1 (en)	2004-04-22
BR0313534A (pt)	2005-07-12
IL166534A (en)	2012-05-31
DK1539739T3 (da)	2011-03-07
CA2496127C (en)	2012-05-29
SI1539739T1 (sl)	2011-04-29

Publication	Publication Date	Title
UA83467C2 (ru)	2008-07-25	Соединения пиперидинила, которые селективно связывают рецепторы интегрина
Krause et al.	2002	The Ena/VASP enigma
Emmer et al.	2010	Molecular mechanisms of protein and lipid targeting to ciliary membranes
Hong et al.	2015	PI (3, 5) P2 controls endosomal branched actin dynamics by regulating cortactin–actin interactions
Janson et al.	2005	Efficient formation of bipolar microtubule bundles requires microtubule-bound γ-tubulin complexes
Terai et al.	2006	JRAB/MICAL-L2 is a junctional Rab13-binding protein mediating the endocytic recycling of occludin
Kuravi et al.	2006	Dynamin-related proteins Vps1p and Dnm1p control peroxisome abundance in Saccharomyces cerevisiae
Nguyen et al.	2007	Antigen 84, an effector of pleiomorphism in Mycobacterium smegmatis
Huang et al.	2014	Morin inhibits sortase A and subsequent biofilm formation in Streptococcus mutans
Dunn et al.	2008	The Toxoplasma gondii dense granule protein GRA7 is phosphorylated upon invasion and forms an unexpected association with the rhoptry proteins ROP2 and ROP4
Ikenouchi et al.	2013	Sphingomyelin clustering is essential for the formation of microvilli
Baxt et al.	2010	Downregulation of an Entamoeba histolytica rhomboid protease reveals roles in regulating parasite adhesion and phagocytosis
Agudo-Ibáñez et al.	2015	H-ras distribution and signaling in plasma membrane microdomains are regulated by acylation and deacylation events
Yoshihara et al.	2002	pilG gene cluster and split pilL genes involved in pilus biogenesis, motility and genetic transformation in the cyanobacterium Synechocystis sp. PCC 6803
Carmeille et al.	2021	Actin and an unconventional myosin motor, TgMyoF, control the organization and dynamics of the endomembrane network in Toxoplasma gondii
Truffi et al.	2014	RPTPα controls epithelial adherens junctions, linking E-cadherin engagement to c-Src-mediated phosphorylation of cortactin
Verma et al.	2015	Insights into endosomal maturation of human holo‐transferrin in the enteric parasite E ntamoeba histolytica: essential roles of R ab7 A and R ab5 in biogenesis of giant early endocytic vacuoles
Nakatsuji et al.	2008	Involvement of actinin-4 in the recruitment of JRAB/MICAL-L2 to cell-cell junctions and the formation of functional tight junctions
Wijgaerts et al.	2017	The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer
Zhang et al.	2022	ROS and calcium oscillations are required for polarized root hair growth
Choi	2018	Upstream paths for Hippo signaling in Drosophila organ development
Danescu et al.	2021	Symmetry and fluctuation of cell movements in neural crest-derived facial mesenchyme
Jurk et al.	2022	Novel GATA1 variant causing a bleeding phenotype associated with combined platelet α-/δ-storage pool deficiency and mild dyserythropoiesis modified by a SLC4A1 variant
Assar et al.	2020	Loss of the essential autophagy regulators FIP200 or Atg5 leads to distinct effects on focal adhesion composition and organization
Chen et al.	2011	Protein 4.1 R regulates cell adhesion, spreading, migration and motility of mouse keratinocytes by modulating surface expression of β1 integrin